Major Inquiry Into EMA Pre-Submission Meetings And Bias Risk Concludes
Executive Summary
The European Ombudsman has recommended how the European Medicines Agency can avoid even the perception that the decisions it takes on marketing authorization applications are influenced by the pre-submission interactions it has with drug developers.
You may also be interested in...
EMA Heeds Ombudsman’s Advice On Avoiding Perception Of Bias In Drug Evaluations
An inquiry by the EU Ombudsman has prompted the European Medicines Agency to introduce changes to ensure that its experts, who advise companies in the premarket phase, are not appointed to evaluate marketing applications for the same drugs.
Ombudsman Probes Whether Industry Can Influence EMA In Pre-Submission Meetings
The European Medicines Agency’s practice of holding pre-submission meetings with drug developers is being investigated by the European Ombudsman, who believes there is scope to make such interactions more transparent to tackle concerns over possible bias.
Advanced Therapy Developers Urged To Monitor Major EU Proposal On Using Blood, Tissues & Cells
Companies have the opportunity to tell the European Commission what they think about its proposed regulation that would overhaul the rules governing the use of substances of human origin.